These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 30370132)

  • 1. Management of stage IA
    Pirker R
    J Thorac Dis; 2018 Sep; 10(Suppl 26):S3260-S3262. PubMed ID: 30370132
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
    Lin CY; Wu YM; Hsieh MH; Wang CW; Wu CY; Chen YJ; Fang YF
    PLoS One; 2017; 12(10):e0186567. PubMed ID: 29065153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
    J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma.
    Zhang J; Shao J; Zhu L; Zhao R; Xing J; Wang J; Guo X; Tu S; Han B; Yu K
    Oncotarget; 2017 Sep; 8(43):74846-74855. PubMed ID: 29088828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.
    Zhang Y; Shen J; Simone CB; Cappuzzo F; Fong KM; Rosell R; Chang JY; Ampollini L; Choi JI; He J; Jiang T;
    J Thorac Dis; 2018 Jun; 10(6):3883-3890. PubMed ID: 30069390
    [No Abstract]   [Full Text] [Related]  

  • 8. Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test.
    Qu BL; Cai BN; Yu W; Liu F; Huang YR; Ju ZJ; Wang XS; Ou GM; Feng LC
    Neoplasma; 2016; 63(1):158-62. PubMed ID: 26639246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.
    Wang DH; Lee HS; Yoon D; Berry G; Wheeler TM; Sugarbaker DJ; Kheradmand F; Engleman E; Burt BM
    Clin Cancer Res; 2017 Feb; 23(3):778-788. PubMed ID: 27496865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma.
    Schneeberger VE; Ren Y; Luetteke N; Huang Q; Chen L; Lawrence HR; Lawrence NJ; Haura EB; Koomen JM; Coppola D; Wu J
    Oncotarget; 2015 Mar; 6(8):6191-202. PubMed ID: 25730908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
    Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
    Chen L; Fu M; Zhou J; Yao Y; Zhou J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.
    Zhang J; Wu J; Tan Q; Zhu L; Gao W
    J Thorac Oncol; 2013 Sep; 8(9):1196-202. PubMed ID: 23945388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
    Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
    Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.
    Takahashi M; Shigematsu Y; Ohta M; Tokumasu H; Matsukura T; Hirai T
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):54-9. PubMed ID: 24131786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
    Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
    Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
    Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
    [No Abstract]   [Full Text] [Related]  

  • 19. Radiologic Predictors for Clinical Stage IA Lung Adenocarcinoma with Ground Glass Components: A Multi-Center Study of Long-Term Outcomes.
    Li Z; Ye B; Bao M; Xu B; Chen Q; Liu S; Han Y; Peng M; Lin Z; Li J; Zhu W; Lin Q; Xiong L
    PLoS One; 2015; 10(9):e0136616. PubMed ID: 26339917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy.
    Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
    Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.